Related references
Note: Only part of the references are listed.Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
Gisle Langslet et al.
CARDIOVASCULAR DRUGS AND THERAPY (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia
Sofia Perez-Calahorra et al.
ATHEROSCLEROSIS (2019)
LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia
Martin P. Bogsrud et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study
Barbara Iyen et al.
ATHEROSCLEROSIS (2019)
Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry
P. Barton Duell et al.
ATHEROSCLEROSIS (2019)
Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study
Leopoldo Perez de Isla et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register
Steve E. Humphries et al.
ATHEROSCLEROSIS (2019)
Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting
Jesus M. Martin-Campos et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death
Henriette Walaas Krogh et al.
EUROPEAN HEART JOURNAL (2016)
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States Data From the CASCADE-FH Registry
Emil M. deGoma et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2016)
Real-World Evidence - What Is It and What Can It Tell Us?
Rachel E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Statin use prior to first myocardial infarction in contemporary patients: Inefficient and not gender equitable
Imra Kulenovic et al.
PREVENTIVE MEDICINE (2016)
Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994-2009, a registry study
Liv Mundal et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2016)
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States Data From the CASCADE-FH Registry
Emil M. deGoma et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2016)
The GRACE Checklist: A Validated Assessment Tool for High Quality Observational Studies of Comparative Effectiveness
Nancy A. Dreyer et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2016)
The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement
Eric I. Benchimol et al.
PLOS MEDICINE (2015)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)
Identification of people with heterozygous familial hypercholesterolemia
Annie Haase et al.
CURRENT OPINION IN LIPIDOLOGY (2012)
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART)
Nelva Mata et al.
LIPIDS IN HEALTH AND DISEASE (2011)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
Andrew Neil et al.
EUROPEAN HEART JOURNAL (2008)
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
Jorie Versmissen et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Cardiovascular disease and mortality in statin-treated patients with familial hypercholesterolemia
MF Mohrschladt et al.
ATHEROSCLEROSIS (2004)
Definition of metabolic syndrome - Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition
SM Grundy et al.
CIRCULATION (2004)
Share Paper
